Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
19 déc. 2024 07h00 HE
|
Oruka Therapeutics, Inc.
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
18 déc. 2024 07h00 HE
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
19 nov. 2024 08h00 HE
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13 nov. 2024 16h25 HE
|
Oruka Therapeutics, Inc.
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro...
Oruka Therapeutics to Present at Multiple November Investor Conferences
04 nov. 2024 07h00 HE
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
25 sept. 2024 07h08 HE
|
Oruka Therapeutics, Inc.
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding...
Oruka Therapeutics Announces $200 Million Private Placement
12 sept. 2024 07h05 HE
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new...
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
12 sept. 2024 07h00 HE
|
Oruka Therapeutics, Inc.
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
03 sept. 2024 07h00 HE
|
Oruka Therapeutics, Inc.
Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to...
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
26 juin 2024 08h00 HE
|
Oruka Therapeutics, Inc.
Paul Quinlan joins as General Counsel Alan Lada joins as VP of Investor Relations Kristine Ball, President & CEO of Antiva Biosciences, appointed to Board of Directors MENLO...